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Introduction {#bpa12514-sec-0001}
============

The 2013 International League Against Epilepsy (ILAE) classification of hippocampal sclerosis (HS) in temporal lobe epilepsy (TLE) [8](#bpa12514-bib-0008){ref-type="ref"} was introduced to integrate previous terminology and provide a robust semiquantitative scoring scheme that could be of potential clinical and prognostic relevance to patients undergoing epilepsy surgery. It has subsequently been implemented in recent reported series of TLE patients [10](#bpa12514-bib-0010){ref-type="ref"}, [12](#bpa12514-bib-0012){ref-type="ref"}, [28](#bpa12514-bib-0028){ref-type="ref"}, [33](#bpa12514-bib-0033){ref-type="ref"}, [48](#bpa12514-bib-0048){ref-type="ref"}. This classification includes the segregation of the common or typical pattern of HS (type 1, with neuronal loss in CA4 and CA1) from type 2 HS (neuronal loss restricted to CA1 subfield) and type 3 HS (neuronal loss restricted to CA4 subfield) based on NeuN stained sections. In practice, however, it can be difficult in some cases to distinguish type 1 from type 2 HS based on determining CA4 neuronal loss with nuclear NeuN immunolabeling.

Nevertheless, there is emerging data suggesting the ILAE classification system enables the identification of HS/TLE phenotypes that could account for clinical variability. HS subtypes may be predictive of seizure‐free outcomes following surgery [12](#bpa12514-bib-0012){ref-type="ref"}, [28](#bpa12514-bib-0028){ref-type="ref"} and subtypes of HS and patterns of subfield neuronal loss have been associated with specific memory impairments, either pre‐ or postoperatively, that can occur with TLE. In particular, type 2 HS has been associated with preserved declarative memory prior to surgery [12](#bpa12514-bib-0012){ref-type="ref"}, [33](#bpa12514-bib-0033){ref-type="ref"} although not in all surgical cohorts [48](#bpa12514-bib-0048){ref-type="ref"}. These different findings between series may relate to the relatively smaller numbers of type 2 HS cases available for study. In addition, loss of dentate gyrus (DG) granule cells in TLE [12](#bpa12514-bib-0012){ref-type="ref"}, [30](#bpa12514-bib-0030){ref-type="ref"} has also been linked with reduced preoperative memory capacity. There is marked plasticity and reorganization of the DG in HS/TLE exemplified by the reorganization of the mossy fiber pathway [40](#bpa12514-bib-0040){ref-type="ref"}, alterations of hippocampal regenerative capacity [11](#bpa12514-bib-0011){ref-type="ref"}, reduction of calbindin protein in granule cells [23](#bpa12514-bib-0023){ref-type="ref"}, astroglial abnormalities [19](#bpa12514-bib-0019){ref-type="ref"}, altered zinc signaling [38](#bpa12514-bib-0038){ref-type="ref"} as well as neurodegeneration including tau accumulation [22](#bpa12514-bib-0022){ref-type="ref"}, all of potential relevance to the memory dysfunction in HS/TLE.

Our aim was to better characterize patterns of HS, associated regenerative and degenerative alterations and correlate these with preoperative memory function and postoperative outcomes including memory decline, in a large series of patients operated for TLE. We included cases that were either typical ILAE type 1 or type 2 HS as well as a group that we considered to have indeterminate patterns of sclerosis (between type 1 and 2), as judged by NeuN qualitative evaluation. MAP2 shows more confluent subfield immunolabeling in the normal CA4 of cell soma and dendritic networks. As the ILAE 2013 system is based on a qualitative assessment of overall NeuN labeling rather than actual neuronal cell counts, we hypothesized that MAP2 could provide a more sensitive qualitative evaluation in these indeterminate HS cases. A further aim was therefore to quantitate, compare and validate the usefulness of these markers for HS subtyping using a rapid automated analysis method.

Methods {#bpa12514-sec-0002}
=======

The cases were selected from the UCL Epilepsy Society Brain and Tissue Bank acquired over two decades (1994--2015). The study has ethical approval and patients consented for research. Applying current ILAE criteria for HS based on semiquantitative evaluation of NeuN staining [8](#bpa12514-bib-0008){ref-type="ref"}, we included 52 cases with type 1, 15 cases with unequivocal type 2 HS and 18 indeterminate cases (Ind‐HS) where it was not possible to classify between type 1 and 2 HS based on qualitative evaluation of neuronal loss on NeuN in CA4 using ILAE criteria [8](#bpa12514-bib-0008){ref-type="ref"}. The type 2 and Ind‐HS cases represented all cases available for study in our archive, cases only being excluded if there was a lack of consent for research or sufficient tissue was not available. In addition, we included seven TLE cases with No‐HS as a comparison for neuronal density measurements only. The clinical features of the HS groups are presented in Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"} and the No‐HS cases in *Supporting Information* Table S1.

###### 

Clinical features of ILAE subtypes compared to patients with indeterminate HS. Abbreviations: GS = secondary generalized seizures. *N* = the total number of cases in the group that data was available for.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical group                                           TYPE 1 HS                                      TYPE 2 HS                                       IND‐HS           
  -------------------------------------------------------- ---------------------------------------------- ----------------------------------------------- ---------------- ------------------------------------------------
  Number of cases                                          52                                             15                                              18               

  Gender                                                   Male/Female                                    22/30                                           5/10             9/9

  Age of onset                                             11.6 (1--41)                                   11.6 (0--21)                                    16.25 (9‐22)     

  Mean (range)                                                                                                                                                             

  years                                                                                                                                                                    

  Age at surgery                                           35.6 (18--55)                                  35.4 (21--53)                                   27.34 (24--31)   

  Mean (range)                                                                                                                                                             

  years                                                                                                                                                                    

  Side operated                                            Left/right                                     29/23                                           8/7              6/12

  Seizure types (% of cases)                               SPS                                            59.6                                            64.3             55.6

  CPS                                                      94.2                                           92.9                                            100              

  GS                                                       78.8                                           85.7                                            72.2             

  IPI (% of cases)                                         Seizure                                        53.8 [\*](#bpa12514-note-0002){ref-type="fn"}   50               44.4[\*\*](#bpa12514-note-0002){ref-type="fn"}

  Head Injury                                              9.6                                            14.3                                            0                

  Other                                                    11.5                                           0                                               5.6              

  None                                                     21.2                                           35.7                                            44.4             

  Preoperative memory dysfunction (% of cases)\            Moderate Verbal function deficit (L/R)         53%[^†^](#bpa12514-note-0003){ref-type="fn"}    54%              33%
  *N* = number of cases with deficit/total tested                                                                                                                          

  (67%/36%)                                                (62%/40%)                                      (60%/20%)                                                        

  *N* = 26/49                                              *N* = 7/13                                     *N* = 5/15                                                       

  Severe Verbal function deficit                           24.4%                                          23.1%                                           6.3%             

  *N* = 11/45                                              *N* = 3/13                                     *N* = 1/16                                                       

  Moderate Visual function deficit (L/R)                   50%[^†^](#bpa12514-note-0003){ref-type="fn"}   69.2%                                           40%              

  (46%/55%)                                                (62.5%/80%)                                    (40%/40%)                                                        

  *N =* 24/48                                              *N =* 9/13                                     *N =* 6/15                                                       

  Severe Visual function deficit                           9.5%                                           33.3%                                           25%              

  *N =* 2/21                                               *N =* 2/6                                      *N =* 1/4                                                        

  Moderate deficit in naming\                              51.2%                                          76.9%                                           46.7%            
  (L/R)                                                                                                                                                                    

  (58%/42%)                                                (100%/40%)                                     (100%/20%)                                                       

  *N =* 22/43                                              *N =* 10/13                                    *N =* 7/18                                                       

  Severe deficit in naming                                 27.9%                                          23.1%                                           33.3%            

  *N =* 12/43                                              *N =* 3/13                                     *N =* 5/15                                                       

  Postoperative memory decline in function (% of cases)\   Decline in verbal function                     22%                                             22%              27%
  *N* = number of cases with deficit/total tested                                                                                                                          

  *N =* 8/37                                               *N =* 2/9                                      *N =* 4/15                                                       

  Decline in visual function                               13%                                            11%                                             13%              

  *N =* 5/38                                               *N =* 1/9                                      *N =* 2/15                                                       

  Decline in naming                                        26%                                            10%                                             7.1%             

  *N =* 10/38                                              *N =* 1/10                                     *N =* 1/14                                                       

  Outcome\                                                 1 year                                         69%                                             50%              56%
  SF (% of cases)\                                                                                                                                                         
  (Number of cases)                                                                                                                                                        

  \(52\)                                                   \(14\)                                         \(18\)                                                           

  2 year                                                   60%                                            36%                                             56%              

  \(50\)                                                   \(11\)                                         \(18\)                                                           

  5 year                                                   66%                                            44%                                             58%              

  \(38\)                                                   \(9\)                                          \(12\)                                                           

  10 year                                                  69%                                            43%                                             20%              

  \(13\)                                                   \(7\)                                          \(5\)                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Initial precipitating injuries: "seizure" group includes a childhood seizure or Febrile Seizure; other category includes any other childhood event including episode of encephalitis/meningitis.

In 3.8%\* and 5.6%\*\* of these cases indicated more than one type of IPI was reported. Partial seizures were grouped into simple (SPS) and complex partial (CPS) in this dataset. The postsurgical outcome was classified using the ILAE system and in this table grouped as seizure free (SF). There was no statistical difference between these clinical factors in the three selected groups.

^†^The type 1 HS cases were selected to include cases both with and without memory decline. For definitions of severe and moderate memory deficits, refer to the main text.

Immunostaining {#bpa12514-sec-0003}
--------------

In each case a representative formalin‐fixed and paraffin‐embedded tissue block was selected from the hippocampal resection which showed maximal representation of all subfields including the DG. Sections were cut at 5 μm thickness and immunohistochemistry staining was carried out using an antibody panel (see *Supporting Information* Table S2 for antibodies, sources, dilutions and methods): MAP2, NeuN (neuronal loss), ZnT3 \[for mossy fiber pathway sprouting [13](#bpa12514-bib-0013){ref-type="ref"}\] and AT8 (phosphorylated tau) was carried out on the entire HS series and calbindin, olig2, MCM2 and nestin markers (hippocampal reorganization/regeneration) were carried out on 40 type 1 HS cases which were selected to include equivalent numbers with or without a preoperative memory deficit to identify pathological alterations that could be predictive of memory loss.

Quantitative analysis {#bpa12514-sec-0004}
---------------------

All pathology measurements were carried out blinded to the cognitive data and details of the quantitative methods are summarized in Table [2](#bpa12514-tbl-0002){ref-type="table-wrap"}. Semi‐quantitative scores were carried out by two observers with good agreement (Kappa index 0.8--0.9); for cases with disparity in the grade, the slide was reviewed by a third person and a consensus was achieved.

###### 

Outline of the methods for quantitative and qualitative evaluation of each pathological feature in hippocampal sclerosis cases with specified immunomarkers.

  Measurement                                                     Method
  --------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NeuN and MAP2 hippocampal subfield analysis for neuronal loss   *Quantitative evaluation*: Sections scanned at x40 and digitized (Leica SCN400 scanner, Leica Microsystems, UK)Six regions of interest (ROIs) were manually defined using Definiens Developer XD 64 software (Definiens AG Munich, Germany): dentate gyrus, subiculum, CA4[\*](#bpa12514-note-0004){ref-type="fn"}, CA3, CA2 and CA1[^†^](#bpa12514-note-0005){ref-type="fn"}Definiens software was trained to automatically detect immunostained structures corresponding to (i) neuronal nuclei (NeuN) or (ii) neuronal cell body and dendrites (MAP2)Labeling index (LI) \[percentage of immunostained area/field fraction[^‡^](#bpa12514-note-0006){ref-type="fn"}\] for each subfield calculated
  MAP2 labeling of basal dendrites on granule cells               *Semiquantitatively scored*: Rare dendritesModerate numbers of granule cells with basal dendritesMany/majority of granule cells have basal dendrites
  Olig2 and MCM2 in dentate gyrus                                 *Quantitative evaluation*: Section tiled at ×2 magnification (Nikon eclipse microscope) using Image Pro Plus (Media Cybernetics, Cambridge, UK)The dentate gyrus was outlined and images captured at ×40 representing this entire area (mean 55 fields/case; range 23--111)Positively labeled nuclei were tagged and the mean number of cells/μm^2^ calculated
  Nestin immunolabeling                                           *Quantitative evaluation*: Slides scanned as for NeuN (above)Using Definiens software, the LI was quantified in four nonoverlapping ROI: granule cell layer, subgranular zone, CA4 and CA1
  ZnT3 evaluation for Mossy fiber pathway sprouting               *Semiquantitatively scored*: Mossy fiber pathway sprouting in the molecular layer was semiquantified using a three‐point scale:0: no sprouting/labeling1: weak or focal labeling2: intense labelingThe presence of a residual mossy fiber pathway[^§^](#bpa12514-note-0007){ref-type="fn"}:0--2 (as above)Axonal sprouting in the subgranular zone:0--2 (as above)
  Calbindin in granule cell layer                                 *Semiquantitatively scored*: 0: total loss/absent expression in granule cells1: severe loss/rare labeled granule cells2: partial loss/approximately half granule cells labeled[^¶^](#bpa12514-note-0008){ref-type="fn"}3: retained/virtually all granule cells labeled
  AT8 labeling for hippocampal phosphorylated tau                 *Semiquantitatively scored*: Six point "modified Braak" tau scoring scale, in any hippocampal subfield, dentate gyrus, subiculum, alveus/white matter:0: negative1: rare grains2: rare threads3: few grains or threads4: moderate neuropil threads/neuronal labeling5: marked deposition[\*\*](#bpa12514-note-0009){ref-type="fn"}

\*For CA4 ROI care was taken to exclude the basal dendrite zone of the granule cells in MAP2 sections.

^†^In the majority of cases all six regions were acquired.

^‡^Labeling index (LI) refers to the percentage/index of immunostained area, that is, the fraction of each digitized high power field that is immunolabeled with an intensity above the set threshold.

^§^Synaptic‐like positive labeling in CA4 and CA3.

^¶^The pattern of positive labeling restricted to the dispersed granule cells only, as previously reported in HS [2](#bpa12514-bib-0002){ref-type="ref"}, [26](#bpa12514-bib-0026){ref-type="ref"} was also noted if present or not.

\*\*AT8 labeling of level 5 was equivalent to Braak stage IV in hippocampus.

Cognitive measures {#bpa12514-sec-0005}
------------------

Preoperative cognitive data was compared to retest data at 1 year following surgery, as previously described [43](#bpa12514-bib-0043){ref-type="ref"} and were available for the majority of patients from routine surgical evaluations undertaken at the National Hospital. Memory was assessed with the List Learning and Design Learning subtests from the Adult Memory & Information Processing Battery prior to 2007 and its successor the Brain Injury Rehabilitation Trust (BIRT) Memory and Information Processing Battery from 2007. These measures have previously been shown to be sensitive to hippocampal pathology [1](#bpa12514-bib-0001){ref-type="ref"}. Naming capacity was assessed using the graded naming test (GNT) [5](#bpa12514-bib-0005){ref-type="ref"}, a measure sensitive to dominant temporal lobe resections [9](#bpa12514-bib-0009){ref-type="ref"}. Preoperatively patients were classified as having a moderate verbal or visual memory deficit if they scored 1 SD or more below average, and as having a severe deficit if they scored 2 SD or more below average. A patient was classified as having experienced a postoperative decline in verbal memory, visual memory and GNT capacity if their postoperative scores declined more than would be expected from retesting on the basis of the reliable change indices (with a confidence interval of 90%) [6](#bpa12514-bib-0006){ref-type="ref"}.

Clinical data and statistical methods {#bpa12514-sec-0006}
-------------------------------------

The duration and age at onset of epilepsy, any initial precipitating injuries (IPI) and outcomes following surgery were recorded. Statistical analysis was carried out between HS groups, pathology measures, psychometric and clinical data using SPSS (version 21 for windows) and included nonparametric tests (Mann--Whitney and Kruskall--Wallis tests) between HS groups and the MANOVA for multivariate analysis of factors in relation to psychometric categories; *P* values of \<0.05 were regarded as significant.

Results {#bpa12514-sec-0007}
=======

Application of MAP2 in classifying indeterminate HS subtypes {#bpa12514-sec-0008}
------------------------------------------------------------

MAP2 highlighted better preservation of CA4 neuronal and dendritic labeling in Ind‐HS compared to type 1 HS cases (Figure [1](#bpa12514-fig-0001){ref-type="fig"}A,B) with comparable intensity to type 2 HS (Figure [1](#bpa12514-fig-0001){ref-type="fig"}C). By comparison, with NeuN labeling the CA4 neuronal densities in Ind‐HS cases appeared intermediate between type 1 and 2 on qualitative assessment alone (Figure [1](#bpa12514-fig-0001){ref-type="fig"}D--F). Quantitative and statistical analysis with whole slide scanning analysis confirmed that with NeuN, CA4 LI in Ind‐HS was between type 1 and 2 HS and statistically different from both (*P* \< 0.0001) (Figure [1](#bpa12514-fig-0001){ref-type="fig"}G--I). With MAP2, however, CA4 LI in Ind‐HS cases was not statistically different to type 2 HS (*P* = 0.07) but different from type 1 HS (*P* = 0.01) (Figure [1](#bpa12514-fig-0001){ref-type="fig"}J--L). Furthermore, compared to LI in No‐HS cases, there was a mean relative reduction of MAP2 LI in CA4 of 36% in type 1 HS compared to only 8% in Ind‐HS and 0% in type 2 HS. Ratios of CA4/CA1 LI for NeuN (Figure [1](#bpa12514-fig-0001){ref-type="fig"}M) and MAP2 (Figure [1](#bpa12514-fig-0001){ref-type="fig"}N) also confirmed the utility of MAP2 in statistically classifying Ind‐HS as similar to type 2 HS.

![*Hippocampal sclerosis (HS) patterns with NeuN and MAP2*. Comparison of labeling in type 1 HS (**A,D**), type 2 HS (**C,F**) and indeterminate HS (Ind‐HS) (**B,E**) for MAP2 (**A,B,C**) and NeuN (**D,E,F**). MAP2 and NeuN both clearly demonstrated the neuronal loss in CA1 in all HS subtypes. Arrow heads indicate regions with patchy neuronal loss in CA4 and the hilus in Ind‐HS, particularly in the subgranular zone, but with overall strong CA4 labeling in MAP2 (**B**). **G--L.** Bar graphs of the labeling index (LI) for NeuN (**G,H,I**) and MAP2 (**J,K,L**) between subtypes of HS. **G**. There was a significant difference in NeuN LI between type 1 and type 2 HS cases in this series in all subfields except for CA1 and the subiculum confirming the distinct patterns of neuronal loss (*P* \< 0.001 to *P* \< 0.0001). **H.** Comparison of type 1 and Ind‐HS with NeuN showed significant differences in the LI in only CA4 (*P* \< 0.0001) whereas **I** between type 2 and Ind‐HS, differences were observed for all subfields except CA1 and the subiculum (*P* \< 0.006 to *P* \< 0.0001). **J**. MAP2 LI also showed significant differences between type 1 and type 2 for CA4 (*P* \< 0.0001). **K.** Comparison of type 1 and Ind‐HS, with MAP2 the LI showed differences in CA4 (*P* = 0.01) whereas (**L**) there were no significant differences between type 2 and Ind‐HS cases for any subfield on MAP2. **M.** Box plots of mean CA4/CA1 ratios for NeuN are highest in type 2 HS with significant differences between all three groups whereas MAP2 classifies Ind‐HS as similar to type 2 HS. Statistical differences are shown as (\**P* \< 0.01--0.001, \*\**P* \< 0.0001). The values for the dentate gyrus (DG), labeling index in G to I are shown as ×10^−1^ for presentation purposes. Bar for **A** to **F** is 1 mm.](BPA-28-143-g001){#bpa12514-fig-0001}

Cognitive performance in relation to HS type and hippocampal neuronal loss {#bpa12514-sec-0009}
--------------------------------------------------------------------------

### Moderate deficit {#bpa12514-sec-0010}

Cases with moderate preoperative verbal, visual memory and GNT deficits were represented in both type 2 and Ind‐HS groups (in addition to the selected type 1 HS group) (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}); although deficits were noted more frequently in type 2 than Ind‐HS for all three domains, there were no significant differences between these two groups. Moderate deficits in verbal memory were more common in left than right sided resections (63% vs. 37%) (*P* = 0.004) and similarly for GNT deficits (65% vs. 35%) (*P* = 0.002) over all cases. A significant left sided predominance in cases with GNT deficits was also noted in type 2 HS (*P* = 0.016) and Ind‐HS (*P* = 0.013) with all left sided resections in these HS groups showing this deficit (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}).

### Severe deficit {#bpa12514-sec-0011}

Cases with severe preoperative verbal, visual memory and GNT deficits were represented in both type 2 and Ind‐HS groups, but with no significant difference between groups (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}).

### Cognitive decline {#bpa12514-sec-0012}

Verbal memory decline was present in 32% (14/61), visual memory decline in 13% (8/62) and a decline in naming in 19% (12/62) over all HS cases that had retesting 1 year postoperatively; cases with memory decline in each domain were represented in type 1, type 2 and Ind‐HS with no significant differences between groups (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}).

Comparison with pathology measures showed significant associations between lower mean NeuN or MAP2 LI in CA1, CA4, DG and subiculum subfields with moderate or severe preoperative memory deficits in all cases or HS subtypes as summarized in Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}. Multivariate analysis showed a significant association of these pathology variables with moderate verbal memory deficits. For memory decline, the only significant observation was higher mean MAP2 LI in the subiculum in cases with naming decline postoperatively (Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}).

###### 

Results of statistical analysis between pathology measures and memory deficits. Abbreviation: MRA = multiple regression analysis performed with SPSS to predict the effect of the multiple variables on the memory deficit.

  Cognitive domain                   Subfield              Pathology measurement     Mean LI/value\* in cases with deficit/decline (SD) *N =* number of cases   Mean LI/value\* in cases without deficit/decline (SD) *N* = number of cases   Significance
  ---------------------------------- --------------------- ------------------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------
  Verbal memory deficit (moderate)   CA1                   NeuN LI                   0.008 (0.006) *N =* 35                                                     0.01 (0.008) *N* = 40                                                         *P* = 0.04 (all HS)
  0.007 (0.004) *N* = 24             0.012 (0.01) N = 22   *P* = 0.019 (type 1 HS)                                                                                                                                                            
  CA4                                MAP2 LI               0.3 (0.2) *N =* 37        0.4 (0.18) *N =* 35                                                        *P* = 0.04 (all HS)                                                           
  0.26 (0.16) *N =* 25               0.37 (0.2) *N =* 20   *P* = 0.05 (type 1 HS)                                                                                                                                                             
  DG                                 Basal dendrites\*     1.51 (0.73) *N =* 37      1.92 (0.8) *N =* 38                                                        *P* = 0.025 (all HS)                                                          
  MRA                                All above                                                                                                                  *P* = 0.016 (*R* ^2^ = 0.15) (all HS)                                         
  Visual memory deficit (moderate)   CA1                   MAP2 LI                   0.2 (0.12) *N =* 31                                                        0.3 (0.15) *N =* 36                                                           *P* = 0.042
  Naming deficit (moderate)          DG                    NeuN LI                   0.1 (0.06) *N =* 20                                                        0.14 (0.07) *N =* 20                                                          *P* = 0.03 (Type 1 HS)
  0.25 (0.09) *N =* 10               0.38 (0.03) *N =* 3   *P* = 0.02 (Type 2 HS)                                                                                                                                                             
  CA4                                MAP2 LI               0.31 (0.05) *N =* 7       0.5 (0.15) *N =* 6                                                         *P* = 0.008 (Ind‐HS)                                                          
  MRA                                All above                                                                                                                  Not significant (all HS); *P* = 0.03 (*R* ^2^ = 0.47) (Ind‐HS)                
  Verbal memory deficit (severe)     DG                    Residual MFP\*            1.27 (0.6) *N =* 15                                                        1.56 (0.6) *N =* 57                                                           *P* = 0.013 (all HS[^†^](#bpa12514-note-0011){ref-type="fn"})
  Visual memory deficit (severe)     Subiculum             MAP2 LI                   0.7 (0.06) *N =* 5                                                         0.83 (0.08) *N =* 22                                                          *P* = 0.008 (all HS[^†^](#bpa12514-note-0011){ref-type="fn"})
  Naming deficit (severe)            DG                    NeuN LI                   0.12 (0.08) *N =* 20                                                       0.16 (0.09) *N =* 50                                                          *P* = 0.05 (all HS[^†^](#bpa12514-note-0011){ref-type="fn"})
  Verbal memory decline              None                                                                                                                                                                                                     
  Visual memory decline              CA4                   Nestin LI                 0.23 (0.06) *N =* 3                                                        0.1 (0.06) *N =* 24                                                           *P* = 0.016
  Naming decline                     Subiculum             MAP2 LI                   0.78 (0.13) *N =* 11                                                       0.64 (0.21) *N =* 43                                                          *P* = 0.03 (all HS)
  AT8\*                              55% *N =* 6/11        22% *N =* 10/45           *P* = 0.035 (all HS)                                                                                                                                     
  DG                                 AT8\*                 45.5% *N =* 5/11          11% *N =* 5/45                                                             *P* = 0.008 (all HS)                                                          
  MRA                                All above                                                                                                                  *P* = 0.008 (*R* ^2^ = 0.2)                                                   

Pathology factors showing significant differences between the presence or absence of deficits in each memory domain are listed and the mean values shown, including the labeling index (LI) of immunostaining for NeuN or MAP2 (except for pathology factors indicated with an asterisk, where the semiquantitative score scales are detailed in supplementary methods).

^†^In cases with the severe memory deficits it was not possible to analyze data further for HS subtypes be caused by the small numbers with a severe deficit in each group.

DG pathology in HS types and cognitive measures {#bpa12514-sec-0013}
-----------------------------------------------

### ZnT3 {#bpa12514-sec-0014}

Mossy fiber pathway sprouting with ZnT3 was observed in all HS types (Figure [2](#bpa12514-fig-0002){ref-type="fig"}D,E). Intense ZnT3 mossy fiber pathway sprouting was more frequently observed in type 1 than type 2 HS cases (55% vs. 29%, respectively) with a trend for a significant difference between these groups (*P* = 0.05) (Figure [2](#bpa12514-fig-0002){ref-type="fig"}H); there were no differences in mossy fiber pathway sprouting patterns between type 1 and Ind‐HS groups. A residual mossy fiber pathway was significantly better preserved in both type 2 HS (*P* = 0.003) and Ind‐HS cases (*P* = 0.01) than type 1 HS (Figure [2](#bpa12514-fig-0002){ref-type="fig"}A--C,I). Labeling of sprouted fibers in the subgranular zone with ZnT3 (Figure [2](#bpa12514-fig-0002){ref-type="fig"}D,E) was more prevalent in type 2 than type 1 HS (*P* = 0.01). The presence of basal dendrites on granule cells as visualized with MAP2 varied dramatically between HS cases (Figure [2](#bpa12514-fig-0002){ref-type="fig"}F,G); although more prevalent in type 1 HS the presence of basal dendrites was not significantly different from type 2 and Ind‐HS based on semiquantitative scores (Figure [2](#bpa12514-fig-0002){ref-type="fig"}I). There was a strong positive correlation in all HS cases between the presence of basal dendrites on granule cells and ZnT3 sprouted fibers in the subgranular zone (*P* \< 0.0001). Statistical analysis showed an association between severe preoperative verbal memory deficit and lack of a preserved mossy fiber pathway (Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}, Figure [2](#bpa12514-fig-0002){ref-type="fig"}K) and moderate preoperative verbal memory deficit and the presence of basal dendrites on granule cells (Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}, Figure [2](#bpa12514-fig-0002){ref-type="fig"}L).

![*Mossy fiber pathway, granule cell basal dendrites in relation to hippocampal sclerosis (HS) type and memory function*. **A--E**. ZnT3; **F--G.** MAP2. **A.** Intense labeling of a retained or normal mossy fiber pathway (MFP) trajectory is shown and absent sprouting. **B**. shows moderate labeling of the normal MPF as well as sprouting in the molecular layer and in **C** the pathway is indistinct (the two arrowheads indicate CA3 and one arrowhead CA4 in the MFP in each figure). **D**. ZnT3 labeling in the subgranular zone (SGZ) is present (arrow) with weak MFP sprouting in the molecular layer and a weak residual MFP in CA4 (arrowhead). **E**. shows more intense MFP sprouting in the molecular layer with ZnT3 also showing some sprouted fibers in the SGZ (arrow). **F.** Basal dendrites on granule cells are highlighted with MAP2 and in this case, are very numerous (arrows) forming a mesh of processes in the SGZ. **G.** In other cases, rarer granule cells (arrow) are observed to have basal dendrites. **H**. Bar chart of the presence of MFP sprouting in the molecular layer between HS types showing differences between type 1 and type 2 HS (\**P* = 0.05). **I**. The presence of a better preserved or residual MFP also showed significant differences between HS groups with better preservation in non‐type 1 HS cases (\**P* = 0.01, \*\**P* = 0.003). **J**. The presence and density of basal dendrites on granule cells showed some variation between HS groups, but the differences were not significant. (Of note in the three bar graphs **H** to **J**, the values for Ind‐HS group are always between observed values for type 1 and type 2 HS). **K**. In all HS/TLE cases, the presence of a better preserved or residual MFP (weak + intense) was associated with a lack of severe preoperative verbal memory deficit (\**P* = 0.013). **L**. The presence of basal dendrites in granule cells was associated with the lack of moderate verbal memory deficit (\**P* = 0.025). Bar is equivalent to approximately 1 mm in **A** to **C**, 100 microns in **D** and **E** and 50 μm in **F** and **G**.](BPA-28-143-g002){#bpa12514-fig-0002}

### Calbindin {#bpa12514-sec-0015}

Total loss of calbindin expression in granule cells was noted in 35%, severe loss in 32.5%, partial loss in 30% and no loss in 2.5% of all cases (Figure [3](#bpa12514-fig-0003){ref-type="fig"}A--C). The pattern of restricted calbindin expression in dispersed granule cells only was present in 30% (Figure [3](#bpa12514-fig-0003){ref-type="fig"}D) [2](#bpa12514-bib-0002){ref-type="ref"}, [26](#bpa12514-bib-0026){ref-type="ref"} which significantly correlated with MAP2 basal dendrites on granule cells (*P* = 0.002) and ZnT3 in the subgranular zone (*P* = 0.001). There were no statistical associations between calbindin expression patterns and memory deficits (*Supporting Information* Table S3).

![*Dentate granule cell layer: evidence of regenerative and degenerative pathology changes*. **A--D.** Calbindin immunohistochemistry varied between cases and was semiquantified as **A.** Preserved expression in granule cells and their apical dendrites, **B.** Partial loss of expression in approximately half of granule cells, **C.** Virtual total loss of expression with only interneurons in CA4 showing positivity. **D**. A frequent pattern in HS/TLE is calbindin expression in the dispersed or migrated cell types whereas the basal granule cells are calbindin negative. There was no statistical association between calbindin expression patterns and memory deficit. **E**--**H** AT8/phosphorylated tau immunohistochemistry, common patterns were **E.** Occasional grains and threads in the molecular layer, **F.** More frequent threads and positive neurones in the subiculum, **G.** Labeling of axons in the hippocampal white matter, **H.** Tau positive neurones in the margins of CA1 subfield: The presence of AT8 in the dentate gyrus and subiculum was significantly associated with memory decline postoperatively. **I.** Olig2 immunohistochemistry: Distinct labeling of a proportion of small nuclei in the dentate gyrus, some in a satellite position in relation to the granule cells. **J.** MCM2 immunohistochemistry: Less frequent, small immature nuclei were present through the dentate gyrus but no labeling of mature granule cells was seen. The density of olig2 and MCM2 positive cells declined, but not significantly, with memory deficit. **K**--**L**. Nestin immunohistochemistry: **K.** Labeling of multipolar cells was most prominent in the subgranular zone and in CA4; **L.** Illustration of occasional nestin‐expressing cells in the molecular layer. There was a positive correlation between nestin labeling in CA4 in patients with visual memory decline. Bar is equivalent to approximately 100 μm in **A** to **D**, 20 μm in **E**, **G**--**J** and 75 μm in **F**, **K** and **L**.](BPA-28-143-g003){#bpa12514-fig-0003}

### AT8 {#bpa12514-sec-0016}

In 35% of cases there was no evidence of hippocampal phosphorylated tau (score 0). In 53.3% of cases rare grains or threads were noted (score 1 and 2) (Figure [3](#bpa12514-fig-0003){ref-type="fig"}E) with a few AT8 threads in 10.4% (score 3) and moderate AT8‐positive tau load in 1.3% of cases (score 4); there was no case with a score 5. AT8 was present in the subiculum (47%) (Figure [3](#bpa12514-fig-0003){ref-type="fig"}F), the DG molecular layer (37%) (Figure [3](#bpa12514-fig-0003){ref-type="fig"}E) and axonal‐like fibers in the parahippocampal gyrus white matter (20%) (Figure [3](#bpa12514-fig-0003){ref-type="fig"}G); labeling was noted in the alveus in 9 cases and in 10 cases prominent labeling of horizontal neurones and fibers in the outer part of CA1 pyramidal cell layer (and CA2) was noted (Figure [3](#bpa12514-fig-0003){ref-type="fig"}H). The presence of AT8 in the DG and subiculum was significantly associated with naming decline 1 year postoperatively (Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}).

### Olig2 and MCM2 {#bpa12514-sec-0017}

Labeling was restricted to the nuclei of small, immature, round to ovoid cells in the DG (Figure [3](#bpa12514-fig-0003){ref-type="fig"}I,J); some were occasionally noted in a "satellite" position in relation to mature granule cell neurones. The density of olig2 and MCM2 positive cells were lower in HS cases with severe preoperative verbal and visual memory function but not significantly different to cases without deficit (*Supporting Information* Table S3).

### Nestin {#bpa12514-sec-0018}

Expression in the DG, apart from in the endothelium, was virtually restricted to multipolar cells in the subgranular zone and more prominently in CA4 (Figure [3](#bpa12514-fig-0003){ref-type="fig"}K); occasional multipolar cells in the molecular layer were seen in some cases (Figure [3](#bpa12514-fig-0003){ref-type="fig"}L). There was a positive correlation between nestin LI in CA4 in patients with visual memory decline at 1 year (*P* = 0.016) but not for other hippocampal ROI (Table [3](#bpa12514-tbl-0003){ref-type="table-wrap"}).

Clinical correlations and outcome {#bpa12514-sec-0019}
---------------------------------

There was no significant difference in the epilepsy history between type 1, 2 and Ind‐HS groups, in regard to age of onset and IPI history, although a lack of a reported IPI was more frequent in the atypical/non‐type 1 HS cases (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}). Complete seizure‐freedom was less frequent for type 2 compared to type 1 HS, with Ind‐HS cases falling between these two groups at each period of follow‐up from 1 to 5 years; however, these differences between the groups were not significant (Table [1](#bpa12514-tbl-0001){ref-type="table-wrap"}). There was a correlation between the modified tau score (*R* ^2^ = 0.075) and age at surgery, but not with other clinical factors including age of onset of epilepsy or IPI type including history of head injury.

Discussion {#bpa12514-sec-0020}
==========

HS is the most frequent pathology in TLE and classification of subtypes is currently recommended by the ILAE as it may inform on different clinical syndromes, outcomes and co‐morbidities, including memory impairment [8](#bpa12514-bib-0008){ref-type="ref"}. In this study, we have shown that additional quantitative evaluation of MAP2 enables the classification of equivocal or indeterminate cases, which seem to fall between type 1 and 2 HS based on current ILAE criteria, as being statistically similar to type 2 HS. Nevertheless, memory deficits present before surgery in our cohort do not align with one HS type but correlate with several pathology factors including neuronal loss in several subfields and mossy fiber reorganization. Postoperative memory decline was associated with neurodegenerative and regenerative pathological alterations. These findings suggest that multifactorial patho‐mechanisms could be operational in the memory impairments associated with HS/TLE.

MAP2 highlights both dendritic labeling as well as the neuronal soma, and is confirmed in this study as a useful adjunct to NeuN for the more sensitive evaluation of neuronal preservation in equivocal cases, particularly in subfields as CA4 with lower neuronal densities. We propose that introduction of MAP2 staining in addition to NeuN in equivocal cases can help in routine evaluation of sclerosis patterns. Qualitative impressions of MAP2 were supported by quantitative analysis in this study employing whole slide scanning image analysis systems which are being increasingly applied in routine diagnostic practice [24](#bpa12514-bib-0024){ref-type="ref"}. This technique has advantages over both subjective semiquantitative as well as other quantitative methods [12](#bpa12514-bib-0012){ref-type="ref"}, [41](#bpa12514-bib-0041){ref-type="ref"}, as the entire hippocampus is evaluated and rapidly, automatically analyzed in an unbiased fashion. Based on MAP2 quantitative analysis, Ind‐HS were statistically similar to type 2 HS whereas with NeuN quantitation they fell between type 1 and 2 HS. Interestingly, mossy fiber pathway reorganization which differed between 1 and 2 HS groups was intermediate in Ind‐HS cases which could suggest a pathological continuum in the process of HS. Furthermore, previous studies have reported fewer seizure‐free outcomes following temporal lobe resections in ILAE type 2 compared to type 1 HS [7](#bpa12514-bib-0007){ref-type="ref"}, [14](#bpa12514-bib-0014){ref-type="ref"}, [28](#bpa12514-bib-0028){ref-type="ref"}. In our series, which included a large number of ILAE type 2 cases, lower rates of seizure‐free outcomes were also noted and although not statistically different from type 1 HS cases, the outcomes for the Ind‐HS group were again noted to be intermediate between type 1 and 2.

The hippocampus has a central role in episodic memory [35](#bpa12514-bib-0035){ref-type="ref"} and memory impairment frequently accompanies HS [18](#bpa12514-bib-0018){ref-type="ref"}, [20](#bpa12514-bib-0020){ref-type="ref"} with a dominant role for the left intact hippocampus in verbal memory and the right with visual‐spatial memory, as also reflected in this current series. Temporal lobe surgery has offered a unique opportunity to correlate pathology, in particular the severity and distribution of hippocampal subfield neuronal loss and gliosis, with any memory dysfunction, in an aim to elucidate normal mnemonic pathways and networks and their potential disruption and reorganization in epilepsy [3](#bpa12514-bib-0003){ref-type="ref"}, [10](#bpa12514-bib-0010){ref-type="ref"}, [12](#bpa12514-bib-0012){ref-type="ref"}, [30](#bpa12514-bib-0030){ref-type="ref"}, [46](#bpa12514-bib-0046){ref-type="ref"}. Previous quantitative studies have reported a correlation between reduced left CA1 neuronal densities and preoperative verbal memory deficits [3](#bpa12514-bib-0003){ref-type="ref"}, a pre‐eminent role for the loss of granule cells and memory dysfunction [12](#bpa12514-bib-0012){ref-type="ref"}, [30](#bpa12514-bib-0030){ref-type="ref"} while other studies showed a correlation with overall neuronal loss across hippocampal subfields [46](#bpa12514-bib-0046){ref-type="ref"}. In the present study, we have shown correlations between neuronal loss assessed with whole slide scanning on NeuN and MAP2 in DG, CA1, CA4 and subiculum subfields and moderate to severe preoperative memory dysfunction. We failed to confirm loss restricted to a single subfield associating with either a memory deficit or decline and multivariate analysis also supported a synergistic contribution of multiple pathology factors to memory dysfunction.

Recent studies have also implicated associations between ILAE HS type and memory function. In a series of 13 patients with ILAE type 2 HS, a lack of dysfunction in declarative memory capacity, as assessed by intracarotid amobarbital (WADA) testing in addition to verbal memory tests, was observed; this suggested functional integrity of hippocampal memory networks despite neuronal depletion of the CA1 sector [10](#bpa12514-bib-0010){ref-type="ref"}, [12](#bpa12514-bib-0012){ref-type="ref"}. This finding was supported by a subsequent report of 36 HS/TLE patients in which type 2 HS cases were over‐represented in patients with normal memory scores [33](#bpa12514-bib-0033){ref-type="ref"} although disputed in a further report of six type 2 HS cases who all had impaired memory function [48](#bpa12514-bib-0048){ref-type="ref"}. A "subordinate" role of CA1 in hippocampal memory circuitry is thus still open to debate. The relatively small number of type 2 cases in each of these series might explain these differences reported as well as differences in memory test designs. In our series, only two patients had had a WADA test, a procedure no longer used at our institute to assess memory function. We included all the available cases of type 2 HS from our institute and confirmed preoperative memory deficits were frequent for visual and verbal memory domains with the anticipated left vs. right lateralization patterns. Our findings support that intact memory function is not always present in type 2 HS.

ZnT3 has been recently employed as a robust marker of the mossy fiber pathway and its re‐organization in epilepsy [13](#bpa12514-bib-0013){ref-type="ref"}. Zinc is also known to have important modulatory effects on synaptic transmission [25](#bpa12514-bib-0025){ref-type="ref"} and a role of ZnT3 in cognitive impairment in neurodegenerative diseases has been proposed [39](#bpa12514-bib-0039){ref-type="ref"}, [45](#bpa12514-bib-0045){ref-type="ref"}. Using this marker in our series, mossy fiber pathway sprouting was a common finding with some differences between HS groups including a more prominent residual mossy fiber pathway in type 2 and Ind‐HS than type 1 HS. Furthermore, there was an association between loss of the normal mossy fiber pathway and preoperative verbal memory deficit, suggesting that integrity of this anatomical pathway is involved in functional memory circuits. Coras *et al*, also noted better anatomical preservation of CA4/3 myelinated fibers connecting to the fimbria and subiculum in HS type 2 patients with intact memory functions [12](#bpa12514-bib-0012){ref-type="ref"}. We also noted a great variability in the density of basal dendrites on granule cells between HS cases as highlighted with MAP2. It is known that the number of basal dendrites are increased in HS/TLE and were present in 40% of granule cells in a previous Golgi study [44](#bpa12514-bib-0044){ref-type="ref"}. Similarly, in experimental models, basal dendrites are a feature of immature granule cells, their numbers increase following seizures and they are innervated by mossy fibers and potentially contribute to recurrent excitatory circuits [29](#bpa12514-bib-0029){ref-type="ref"}. We noted that the presence of basal dendrites strongly correlated with ZnT3 labeling of mossy fibers in the subgranular zone, which is in keeping with these experimental findings. Our observation of lower densities of basal dendrites on granule cells in patients with preoperative memory deficit could also imply their contribution to anatomical memory circuits in the damaged hippocampus. In addition, basal dendrites as a surrogate marker of newly generated or immature granule cells could support the concept of an impaired regenerative capacity/plasticity in HS patients with memory deficits.

The subgranular zone is one of the main regenerative sites in the adult human brain with estimates of 700 new cells added per day [34](#bpa12514-bib-0034){ref-type="ref"}. Seizures are known to influence progenitor cell turnover [29](#bpa12514-bib-0029){ref-type="ref"} and previous in‐vitro studies on human epilepsy tissues have correlated loss of granule cell proliferative capacity with memory dysfunction [11](#bpa12514-bib-0011){ref-type="ref"}. In the current series, we selected equal numbers of classical or type 1 HS both with and without memory deficits in an aim to tease out any pathological differences in DG regenerative capacity that could be measured in fixed tissue sections. We utilized cell cycle marker MCM2 to measure overall cell replicative capacity in the hippocampus and olig2 as a marker of oligodendrocyte progenitor cells, previously shown to be the largest population of proliferating cells in tissues from focal epilepsy [16](#bpa12514-bib-0016){ref-type="ref"}. Calbindin is not expressed in immature granule cells and reduced calbindin expression in granule cells is a frequent observation in TLE, particularly in less mature basal granule cells [1](#bpa12514-bib-0001){ref-type="ref"}, [2](#bpa12514-bib-0002){ref-type="ref"}, [26](#bpa12514-bib-0026){ref-type="ref"}. Furthermore, lower calbindin levels in granule cells have been postulated to influence memory capacity, being depleted in Alzheimer\'s disease [36](#bpa12514-bib-0036){ref-type="ref"} and a loss of calbindin has been previously shown in TLE to correlate with verbal memory dysfunction [23](#bpa12514-bib-0023){ref-type="ref"}. In this current study, although differences were noted with our methods, we were unable to confirm a significant correlation between olig2, MCM2 and calbindin labeling with pre‐ or postoperative memory dysfunction in type 1 HS.

Further decline in memory following temporal lobe surgery is reported to occur in up to 25%, with older patients being particularly vulnerable [21](#bpa12514-bib-0021){ref-type="ref"}, [43](#bpa12514-bib-0043){ref-type="ref"}. A better‐preserved hippocampus has been shown to be predictive of greater postoperative decline in verbal memory function [47](#bpa12514-bib-0047){ref-type="ref"} and more significant postoperative memory declines have been reported with ILAE type 2 HS [12](#bpa12514-bib-0012){ref-type="ref"} or better preserved CA1 [3](#bpa12514-bib-0003){ref-type="ref"}. In terms of quantitative confirmation of regional neuronal preservation in the present study, we identified a statistical association between MAP2 labeling only in the subiculum and naming decline at 1 year. However, we also identified an association between the presence of phosphorylated tau pathology in the subiculum and DG and a postoperative decline in naming. The tau load was overall low in this predominantly young adult cohort but correlated with age at surgery and is unlikely to represent either a primary tauopathy or be relevant to the cause of epilepsy. Previous surgical [31](#bpa12514-bib-0031){ref-type="ref"}, [37](#bpa12514-bib-0037){ref-type="ref"} as well as post‐mortem studies in long‐term epilepsy [42](#bpa12514-bib-0042){ref-type="ref"} support an age‐accelerated deposition of tau, with some patterns potentially related to brain injury. Enhanced accumulation of p‐tau has been shown in the molecular layer, granule cells and mossy fibers in association with seizures in Alzheimer\'s disease transgenic mouse models [49](#bpa12514-bib-0049){ref-type="ref"} and tau accumulation is modulated by synaptic activity in experimental systems [37](#bpa12514-bib-0037){ref-type="ref"}. We have also previously shown "epilepsy‐specific" patterns of tau accumulation in the hippocampus in some patients over 50 years old at surgery, including early involvement of the DG [37](#bpa12514-bib-0037){ref-type="ref"}. This study therefore highlights the potential vulnerability of some younger adults with epilepsy to a secondary tauopathy, which may predispose to postoperative memory decline following surgery.

Reactive astrogliosis is a prominent component of HS and plasticity of glial cell populations and functional changes are considered to contribute to disease mechanisms in epilepsy [4](#bpa12514-bib-0004){ref-type="ref"}, [44](#bpa12514-bib-0044){ref-type="ref"} including potential effects on memory [19](#bpa12514-bib-0019){ref-type="ref"}, [32](#bpa12514-bib-0032){ref-type="ref"}. Glial cells exceed brain cells in their complexity, diversity and number, with roles for glial transmitters in memory, including long term memory consolidation [15](#bpa12514-bib-0015){ref-type="ref"}, [27](#bpa12514-bib-0027){ref-type="ref"} and spatial memory [17](#bpa12514-bib-0017){ref-type="ref"}. Previous studies addressing glial populations in relation to memory in HS/TLE have utilized GFAP [3](#bpa12514-bib-0003){ref-type="ref"} and showed no correlation between glial density in any subfield and preoperative neuropsychology test scores. Nestin selectively labels a subset of immature glial cells in the subgranular zone of the hippocampus which contribute to adult neurogenesis [37](#bpa12514-bib-0037){ref-type="ref"}; it is also an intermediate filament that is transiently re‐expressed in reactive, proliferating glia at injury sites. We observed that nestin‐positive glia in type 1 HS had restricted distribution and were more prominent in hilar subgranular zone in HS cases; furthermore, their density was inversely linked to visual memory decline postoperatively.

The limitations of this study include the relatively small numbers of type 2 and Ind‐HS cases compared to type 1 HS cases. Although the surgical specimens are processed following standard laboratory protocols and similar fixation times, we cannot exclude that minor variations could influence overall immunostaining intensity effecting labeling index measurements between cases.

In conclusion, we have shown that MAP2 is a useful adjunct to NeuN in the evaluation of neuronal preservation in CA4 in equivocal, indeterminate HS cases, suggesting that these cases more closely align with type 2 HS. Nevertheless, HS type in our series was not predictive of memory dysfunction or decline, which associated instead with multiple pathological factors, including neuronal and hippocampal pathway integrity, regenerative capacity and degenerative changes.
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